Zenas BioPharma Income Statement (2023-2025) | ZBIO

Income Statement Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Revenue & cost
Revenue 50.00M5.00M10.00M
Operating items
Research & Development 9.35M20.42M22.64M33.81M33.53M49.16M34.91M43.03M34.40M
Selling, General & Administrative 5.02M4.36M4.93M5.89M7.45M11.47M12.41M12.14M13.18M
Other Operating Expenses 5.00M
Operating Expenses 14.38M24.78M27.58M39.70M40.98M60.62M47.33M55.16M52.58M
Operating Income 35.62M-24.78M-27.58M-39.70M-40.98M-55.62M-37.33M-55.16M-52.58M
EBIT 35.62M-24.78M-27.58M-39.70M-40.98M-55.62M-37.33M-55.16M-52.58M
Non-operating items
Other Non Operating Income -0.02M0.79M0.47M1.88M2.38M3.45M3.55M2.96M1.08M
Non Operating Income -0.02M0.79M0.47M1.88M2.38M3.45M3.55M2.96M1.08M
Net income details
EBT 35.62M-24.78M-27.80M-37.98M-38.61M-56.53M-33.78M-52.20M-51.50M
Tax Provisions -0.20M0.02M
Profit After Tax 35.61M-24.59M-27.80M-38.00M-38.61M-52.60M-33.60M-52.22M-51.50M
Income from Continuing Operations 35.62M-24.78M-27.80M-37.98M-38.61M-56.53M-33.57M-52.22M-51.50M
Consolidated Net Income 35.62M-24.78M-27.80M-37.98M-38.61M-56.53M-33.57M-52.22M-51.50M
Income towards Parent Company 35.62M-24.78M-27.80M-37.98M-38.61M-56.53M-33.57M-52.22M-51.50M
Net Income towards Common Stockholders 35.62M-24.78M-27.80M-37.98M-38.61M-56.53M-33.57M-52.22M-51.50M
Additional items
EPS (Basic) 2.42-16.04-17.89-24.23-5.0216.94-0.80-1.25-1.22
EPS (Weighted Average and Diluted) 1.96-16.04-17.89-24.23-5.0216.94-0.80-1.25-1.22
Shares Outstanding (Weighted Average) 26.56M26.56M38.32M41.79M41.79M41.83M41.83M42.11M
Shares Outstanding (Diluted Average) 1.53M1.55M1.57M7.70M13.20M41.80M41.87M42.16M
EBITDA 35.62M-24.67M-27.76M-37.95M-38.66M-52.46M-33.63M-52.46M-51.47M
Tax Rate 0.61%